| abstract |
The present invention provides antibodies that bind to the p9 subunit of human IL-23 and are characterized by high affinity, selectivity and neutralization properties. The antibodies are useful for treating or preventing an autoimmune or inflammatory condition selected from multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, graft versus host disease, lupus, and metabolic syndrome. Antibodies can also be used to treat cancer. |